Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority randomized controlled trial

BACKGROUND: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y(12) inhibitor is recommended for patients with coronary heart disease (CHD) undergoing percutaneous coronary intervention (PCI) to antithrombosis, meanwhile, increasing the risks of gastrointestinal bleeding. Rivaroxaban, a novel or...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Tienan, Gong, Yinghui, Li, Jingyuan, Wang, Yasong, Wang, Xiaozeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031942/
https://www.ncbi.nlm.nih.gov/pubmed/36945020
http://dx.doi.org/10.1186/s13063-023-07236-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031942/
https://www.ncbi.nlm.nih.gov/pubmed/36945020
http://dx.doi.org/10.1186/s13063-023-07236-w

Ejemplares similares